These findings provide further confirmation of the critical role of IL-17A in NASH progression and NASH–HCC transition, indirectly implying the oncogenic role of Th17 in NASH-associated HCC [100]. This evidence concerns the gene IL17A and metabolic dysfunction-associated steatohepatitis.